• S19:E1 – Morning Commute Podcast: Should HER3 Be Considered a Tumor-Agnostic Target in Breast and Lung Cancer?

  • Dec 29 2023
  • Duración: 26 m
  • Podcast

S19:E1 – Morning Commute Podcast: Should HER3 Be Considered a Tumor-Agnostic Target in Breast and Lung Cancer?

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • In this episode, our faculty discuss the widespread expression of human epidermal growth factor receptor 3 (HER3) across tumor types and why clinicians should have HER3 on their radar.

    Visit www.morningcommutepodcast.com/HER3Agnostic1 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.
    Más Menos
activate_primeday_promo_in_buybox_DT
Más Menos

Lo que los oyentes dicen sobre S19:E1 – Morning Commute Podcast: Should HER3 Be Considered a Tumor-Agnostic Target in Breast and Lung Cancer?

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles